ClinicalTrials.gg
CompletedNCT03884348Updated Mar 21, 2019

Tailored H. Pylori Eradication Based on Clarithromycin Resistance

An observational study in Helicobacter Pylori Infection and Antibiotic Resistant Strain, sponsored by Kangdong Sacred Heart Hospital. Completed. Open to participants aged 19 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-03-21.

Sponsored by Kangdong Sacred Heart Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
431
Ages
19 Years to 85 Years
Sex
All
01

Study summary

The investigators investigated the point mutations in the 23S rRNA genes of patients infected with clarithromycin-resistant H. pylori and compared the H. pylori eradication rates based on the identified clinically significant point mutations.

Read the detailed description

Sequencing-based detection of point mutations identified four mutations that were considered clinically significant (A2142G, A2142C, A2143G, A2143C), while all the other mutations were considered clinically insignificant.

Participants who did not have point mutations related to clarithromycin resistance and/or had clinically insignificant point mutations were treated with PAC (proton pump inhibitor, amoxicillin, clarithromycin) for 7 days, while participants with clinically significant point mutations were treated with PAM (proton pump inhibitor, amoxicillin, metronidazole) for 7 days. H. pylori eradication rates were compared between the two groups.

02

Conditions studied

  • Helicobacter Pylori Infection
  • Antibiotic Resistant Strain

Browse trials for

03

In context

Sprains and Strains

246 studies on the registry are indexed under Sprains and Strains; 49 are open to participants now.

This study's enrollment of 431 is above the median of 101 across 79 observational studies indexed under Sprains and Strains.

Browse Sprains and Strains studies →

Lead sponsor

Kangdong Sacred Heart Hospital is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Helicobacter-pylori positive patients with gastritis, ulcer, adenoma

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Helicobacter pylori infection

Exclusion criteria

Exclusion Criteria:

  • H. pylori eradication therapy within 1 year,
  • antibiotics within 4 weeks,
  • surgery for gastric cancer
  • malignant tumors other than gastric cancer
  • end-stage renal disease
  • liver cirrhosis,
  • pregnancy
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
431 participants (actual)
Patient registry
No

Groups and cohorts

  • PAM-treated clarithromycin-resistance group

    Treatment with PPI twice a day, amoxicillin (1000 mg) twice a day, and metronidazole (500 mg) three times a day for 7 days in patients with clinically significant point mutations

    Drug: proton pump inhibitor, amoxicillin, metronidazole

  • PAC-treated nonresistance group

    Treatment with PPI twice a day, amoxicillin (1000 mg) twice a day, and clarithromycin (500 mg) twice a day for 7 day in patients with clinically insignificant point mutations

    Drug: proton pump inhibitor, amoxicillin, clarithromycin

Interventions

06

What researchers measure

Primary outcomes

  1. Helicobacter pylori eradication rate

    Number of participant with successful Helicobacter pylori eradication

    Time frame: 2 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Dec 2018, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2019
First posted
Mar 21, 2019
StartActual
Jan 1, 2017
Primary completionActual
Dec 31, 2018
CompletionActual
Dec 31, 2018
Last update
Mar 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03884348
Lead sponsor
Kangdong Sacred Heart Hospital
Responsible party
Shin, Woon Geon (Principal Investigator, Kangdong Sacred Heart Hospital) — Principal investigator
First posted
Mar 21, 2019
Start date
Jan 1, 2017
Primary completion
Dec 31, 2018
Completion
Dec 31, 2018
Last update
Mar 21, 2019

Study contacts

Woon Geon Shin
principal investigator · Kangdong Sacred Heart Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion